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ABSTRACT 
For some time now modified drug release has been studied and used extensively during the development of pharmaceutical drug 
products because of its advantages over immediate release formulations. As per the forecasting by Global Business Intelligence 
(GBI) research, the growth in oral drug delivery market will uplift in the coming years. Modified release drug products allow at least 
a two-fold reduction in dosing when compared to a drug that is presented in a conventional immediate release form. Modified release 
drug products are designed to release active pharmaceutical ingredient over a longer duration of time; At least, longer than an 
immediate release (I.R) formulation. Many Pharmaceutical companies also utilize the proprietary advantages of Modified release 
formulations to extend the patent life cycle of commercial products thereby bringing in new business.  
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Years ago in 1895, a very well reputed British 
Pharmaceutical Journal predicted "Tablets have had their 
day and will pass away to make room for something 
else." Now, with almost more than 100 years after this 
statement, today, oral solid dosage forms are the leading 
drug delivery systems in the market, and they are not 
going to perish in coming 30 years. The oral route was 
and is still the preferred route of drug administration due 
to its prominent advantages compared to the other 
routes. Conventional oral drug delivery systems are 
known to provide an immediate release of drug, in 
which one cannot control the release of the drug and 
effective concentration at the target site, therefore 
alteration of drug release is required 
1
.  
   However, the sophisticated instrumentation, modern 
mathematical models and computational power have 
revolutionized the entire process of all the aspects of 
formulation and development of drug delivery systems 
in last few decades. Novel drug delivery systems have 
emerged and advanced the concept of drug delivery 




Rationale for development of modified release 
system: 
The main objectives of any drug delivery system are to 
ensure safety and to improve efficacy of drugs as well as 
patient compliance. This is achieved by better control of 
plasma drug levels and less frequent dosing. 
Conventional dosage forms are not able to control the 
rate of drug delivery and provide rapid drug release, to 
maintain a therapeutic level required frequent drug 
administration, which leads to fluctuated level of drug in 
blood and tissues. The concentration of drugs may be 
initially high, that can cause toxic, and/or side effects. 
The concentration quickly falls down below the 
minimum therapeutic level with time elapse. In contrast, 
Modified release dosage forms are not only able to 
maintain therapeutic levels of drug with narrow 
fluctuations but they also make it possible to reduce the 
Gujral et al                                                                                                                 Journal of Drug Delivery & Therapeutics. 2018; 8(4):5-9               
ISSN: 2250-1177                                                                             [6]                                                                             CODEN (USA): JDDTAO 
frequency of drug administration. The concentration of a 
drug released from controlled release dosage forms 
fluctuates within the therapeutic range over a long 
period of time.  
A given formulation exhibits pharmacological response 
only for the time period when the drug blood levels are 
within the therapeutic window or the therapeutic range. 
On administrating the drug by either IV or an oral route 
(Immediate release dosage form), the drug blood levels 
are not achieved within the therapeutic range for an 
extended period of time. On the contrary, to overcome 
this, therapeutic efficacy and safety of drugs can be 
improved by more precise spatial and temporal 
placement within the body, thereby reducing both the 
size as well as the number of doses. A modified-release 
dosage form is defined “as one for which the drug 
release characteristics of time course and/or location are 
chosen to accomplish therapeutic or convenience 
objectives not offered by conventional dosage forms 





Figure 1 Typical drug blood levels versus time profile 
for intravenous and oral route of administration 
Classification: 
The modified release system, i.e. non-immediate release 




1. Delayed release  
2. Sustained release Controlled release, Prolong release 
3. Site specific and receptor release Organ targeting, Cellular targeting, Sub cellular targeting 
 
1) Delayed release: Delayed release systems are those 
systems that use repetitive, intermittent dosing of a drug 
from one or more immediate release units incorporated 
into a single dosage form. Repeat action tablets and 
capsules are the classical examples. A delayed release 
dosage form does not produce or maintain uniform drug 
blood levels within the therapeutic range. The drug 
release pattern is shown in Figure 2. 
 
Figure 2 Typical drug blood levels versus time 
profiles for delayed release 
2) Sustained release: It includes all drug delivery 
systems that achieve slow release of drug over an 
extended period of time. Ideally, a sustained release oral 
dosage form is designed to rapidly release pre-
determined fraction of the total dose (loading dose) into 
gastrointestinal tract, which will produce the desired 
pharmacological response as promptly as possible and 
the remaining fraction of the total dose (maintenance 
dose) is then released at a controlled rate 
 Controlled release: Drug product is designed so that 
the release rate of maintenance dose is equal to the 
elimination rate. The constant blood levels can be 
achieved from controlled release system. 
Prolonged release: Prolonged release dosage forms 
reduce fluctuation in plasma drug levels by slowing 
down the absorption rate due to slower drug release rate. 
It extends the period of time the drug concentration is in 
the therapeutic range but does not maintain constant 
blood levels as controlled release systems.  
 
Figure 3: Drug blood level versus time profile showing 
the relationship between controlled release (A), 
Prolonged release (B), & conventional release (C) 
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3) Site specific and receptor release: In the case of 
site specific release, the target is a certain organ or tissue 
(e.g. in the treatment of arthritis or gout). While for 
receptor release, the target is the particular receptor for a 
drug within an organ or tissue (e.g. H1 and H2 
antagonists located in tumor cells). Both these systems 
satisfy the spatial aspect of drug delivery. This type of 
drug release is difficult to achieve. 
Advantages of modified release dosage form 
(Robinson and Longer 1676)
4-5
 
1. Avoid patient compliance problems 
2. Better drug utilization and employed less total drug 
a. Minimize or eliminate local side effects and systemic 
side effects 
b. Obtain less potentiation or reduction in drug activity 
with chronic use 
c. Minimize drug accumulation with chronic dosing 
3. Improve efficiency in treatment 
4. Cure or control condition more promptly 
5. Improve control of condition i.e. reduce fluctuation 
in drug level 
6. Improve bioavailability of some drugs 
7. Make use of special effects e.g. Sustained release 
aspirin for morning relief of arthritis by dosing 
before bedtime 
8. Economical 




1. Drug with following characteristics cannot be 
given by modified release dosage form. 
a. Drugs with very narrow therapeutic index. 
b. Drugs with erratic absorption from gastrointestinal 
track 
c. Drugs with long biological half life 
d. Drugs which needs to adjust dose regime 
e. Drugs with very high dose 
2. The dose cannot be subdivided as in conventional 
dosage form 
3. Difficult to provide antidote for sustained release 
formulations 
 Factors considering for selection of drugs for the 
development of Modified release dosage forms:
 8-9        
i. Molecular size and diffusivity: Diffusion may be 
defined as a mass transfer of individual molecules of a 
drug substance and mainly by random molecular motion 
associated with concentration gradient. During time 
course of the drug it must diffuse through various 
biological membranes in the body. The drugs in the form 
of modified release dosage form must diffuse through a 
matrix or polymeric membrane. The ability of drug 
diffuse through polymers is called as diffusivity and is a 
function of its molecular weight or molecular size. The 
drugs or polymers which are having high molecular 
weight show very slow release kinetics in sustained 
release device by diffusion through polymeric 
membrane 
ii. PKa- Ionization constant: Ionization constant is one 
of the important properties used to measure the strength 
of an acid or base and determine the charge on the drug 
molecule at any given pH. The ionized forms of drugs 
are poor candidates for sustained or controlled dosage 
form at the absorption site. The drug molecules are 
active only at unionized state and cross rapidly through 
lipoidal membranes than ionized molecules. 
iii. Partition coefficient: The partition coefficient is 
used to measure of how hydrophilic or hydrophobic a 
drug substance is or it’s a measure of Hydrophilicity-
Lipophilicity balance. Partition coefficient influences 
both permeation of drug across the biological membrane 
and diffusion across the rate controlling membrane or 
matrix. The drugs with high partition coefficient are very 
oil soluble and will partition rapidly into various 
membranes in the body and show greater activity. 
iv. Drug Stability: The drug stability is most important 
parameter in the dosage form design. When the drug 
administered orally, it losses through hydrolysis or 
degradation in the GIT. So it is necessary to improve the 
relative bioavailability of drug that is unstable in gastric 
region and such drugs should suitable for delayed 
release dosage form in order to release the drug in the 
intestine. The drugs which are having stability problems 
in the gastric region are less suitable for modified release 
dosage form and design the drug to deliver uniformly 
throughout the gastric region. 
v. Aqueous solubility:
 10-11 
Solubility may define as the 
maximum amount of drug substance that goes into the 
solution form in a specific amount of solvent. The 
solubility of drug substance mainly depends on 
concentration, pressure and solvent used. High solubility 
may define as highest dose strength is soluble in 250mL 
or less of aqueous media over the pH range of 1-7.5.The 
drugs with aqueous solubility influences drug 
dissolution rate and it establishes the concentration in 
solution. The dissolution rate is related to aqueous 
solubility and explained by Noyes-Whitney equation. 
The drug with high solubility and a rapid dissolution rate 
is difficult to control or decrease the dissolution rate and 
slow its absorption. The drug with low solubility 
difficult to sequester a highly soluble dosage form and 
retard the drug release in case of high drug dose. The 
drug with very low solubility and slow dissolution rate 
will exhibit very limited absorption and not provide a 





Development of modified 
release dosage forms for highly soluble drugs is 
becomes challenge to the formulation scientist. These 
drugs will release the drug readily at a faster rate and 
produces untoward effects on oral administration. So, 
considerable attention was needed for the selection of 
polymers to retard the drug release for highly soluble 
drugs. Based on flexibility, desirable drug release and 
cost effective, hydrophilic polymers are most suitable to 
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retard the drug release and various water swellable or 
water soluble with high molecular weight polymers were 
used in hydrophilic matrices such as Hydroxy propyl 
methyl cellulose and Polyethylene oxide. HPMC is most 
commonly used polymer in matrix formulations because 
of their features like pH independent performance, 
excellent stability, suitable for direct compression and 
granulation techniques. Polyethylene oxide also 
commonly used polymer in matrix formulations because 
of their versatile application for direct compression, 
granulation technique, fast hydration and gel formation.
 
Why the need to convert IR to MR? 
Attention in the development of Modified release dosage 
forms in Pharmaceutical industry is increasing day-by-
day as there are more advantages than immediate release 
dosage forms. This is particularly more important to 
innovator companies for the development of modified 
release dosage forms to get additional market exclusivity 
for newly developed modified release dosage forms as 
well as additional Intellectual Property to the company 
by protecting these complex modified release forms with 
Patents and thus delaying the entry of generic products 
to the market. This strategy generally used by Innovator 
companies to shift the market from immediate release 
dosage forms to Modified release dosage forms, once 
after Data exclusivity/Patent is expired for immediate 
release dosage forms and capture all the market, thus 
delaying generic companies to enter the market. Below 
is list of few of the examples of drugs where modified 
release dosage forms are approved after long time of 
immediate release dosage forms are approved, and 
captured the most of the market and become block 
busters
 










date of IR 
Approval 
date of MR 
MR patent No 
& Expiry 
1 Bupropion(Wellbutrin SR) GSK Dec 30,1985 Oct 4, 1996 5358970& 2013 
2 Metformin(Glucophage XR) BMS Mar 3,1995 Oct 13,2000 6475521& 2018 
3 Zolpidem(Ambien CR) SANOFI Dec 16,1992 Sep 2, 2005 6514531& 2020 
4 Nifedipine(Adalat CC) BAYER Nov27,1985 Apr 21,1993 5264446& 2010 
5 Carbamazepine(Carbatrol ) SHIRE Mar11,1968 Sep 30,1997 5912013& 2016 
 
Regulatory approval of Modified release products in 
New Drug Application (NDA)
 15
: 
In principle, FDA approval of MR products in new drug 
applications (NDAs) submitted by innovator firms is 
based on evidence of an adequate drug exposure–
response framework. Exposure can be expressed by 
blood levels or dose, and response by validated clinical 
endpoint(s) or surrogate endpoint(s). The exposure–
response framework should include knowledge of the 
impact that drug input rate and its delivery course have 
on response or established therapeutic range for the MR 
product under consideration. Preferably, a quantitative 
and predictive exposure–response relationship exists, 
and tolerance does not develop over time. In general, 
there are three types of NDAs for MR drug products: (a) 
IR to MR switch, (b) MR to MR switch with unequal 
dosing intervals, and (c) MR to MR switch with equal 
dosing intervals. Regulatory requirements vary with the 
type of NDA submitted to FDA. For example, in the 
case of switching from an IR to an MR product, the key 
question is whether there is an adequate exposure–
response framework established by the previously 
approved IR product. If the answer is yes, no clinical 
efficacy trial may be needed, and the only requirement is 
to conduct three clinical pharmacology studies under 
single-dose (fasting and fed) and steady-state conditions. 
The main goal is to ensure that the new MR product has 
similar exposure course of the drug compared with the 
previously approved product with proven efficacy. If the 
answer is no, one efficacy and/or safety trial may be 
necessary in addition to the three clinical pharmacology 
studies. In the clinical efficacy trial for the MR product, 
a head-to head comparison between the MR and IR 
products is not considered a requirement, and thus NDA 
sponsors opt to do placebo-controlled studies without an 
IR formulation in the trial., NDA sponsors may also be 
asked to perform animal studies with the appropriate 
regimen in addition to the clinical efficacy trial in 
patients.  




In the USA, pharmaceutical equivalents are referred to 
drug products in identical dosage forms that contain 
identical amounts of the identical active drug ingredient 
and meet the identical or compendial or other applicable 
standard of identity, strength, quality, and purity, 
including potency and, where applicable, content 
uniformity, disintegration times, and/or dissolution 
rates. 
IR drug products: pharmaceutical equivalence may 
provide a presumption of therapeutic equivalence, which 
can be further verified by appropriate in vivo 
bioequivalence studies. In fact, these in vivo studies 
may be waived under certain circumstances, e.g., BCS 
class I drugs formulated in rapidly dissolving products.  
MR drug products: In MR drug products, however, 
traditional appraisal of pharmaceutical equivalence may 
not provide a presumption of therapeutic equivalence. 
This is partly because in vitro and in vivo correlations 
(or relationships) might not have been carried out in the 
development of many MR products. In addition, 
excipients used for control of drug release are critical to 
the performance of MR products. To ensure therapeutic 
equivalence of MR products, a scrutiny of 
pharmaceutical equivalence is essential, which may 
include careful characterization of physicochemical 
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properties of the dosage form, purity of the drug 
substance and excipients, solubility, dissolution, and 
stability of the drug/product. 
Additional measures to assess bioequivalence: 
It is generally agreed that the present regulatory criteria 
are adequate in the assessment of bioequivalence for 
many MR formulations with conventional drug release 
profiles in vivo. However, for MR products designed to 
achieve a rapid rise in drug plasma concentrations (and 
thus a rapid onset of therapeutic effect) following 
administration or newer MR products with different 
drug release mechanisms (such as pulsatile- or chrono-
release), other measures in addition to the current 
pharmacokinetic parameters (i.e., AUC and Cmax) may 
be needed for assuring bioequivalence. The use of 
pharmacokinetic/Pharmacodynamic (PK/PD) modeling 
and simulations allows for linking drug concentrations 
to their effects (safety or efficacy) and thus can be used 




Among the various routes of drug delivery oral route is 
most preferred route. But conventional dosage form 
offers few limitations which could be resolved by 
modifying the existing dosage form. Modified drug 
delivery system helps in maintaince of constant plasma 
drug concentration and retards the release rate of drug 
thereby extending the duration of action. 
Geographically, the global modified -release drug 
delivery technology market is classified into regions viz. 
North America, Latin America, Western Europe, 
Eastern Europe, Asia-Pacific, Japan, Middle East and 
Africa. North America will continue to hold the largest 
share in the global controlled-release drug delivery 
technology market due to rising number of NDA and 
ANDA applications being filed by the key players. 
Europe is expected to hold second largest share in the 
global market for modified -release drug delivery 
technology market. As a result of this, the future of the 
modified release tablets seems to be very promising 
especially with the coming up of new molecules which 
will definitely be explored further for better therapeutic 
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